1 Steffens DC, Potter GG. Geriatric depression and cognitive impairment. Psychol Med 2008;38(2):163–75.
2 World Health Organisation. International statistical classification of diseases and related health problems. 10th rev. Genf, 2007.
3 American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition. Washington, DC, 2013.
4 Möller HJ, Bandelow B, Bauer M, Hampel H, Herpertz SC, Soyka M, et al. DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences – part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. Eur Arch Psychiatry Clin Neurosci 2015;265(2):87–106.
5 McKhann GM., Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7(3):263–9.
6 Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43(2):250–60.
7 McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863–72.
8 Goetz CG, Emre M, Dubois B. Parkinson’s disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann Neurol 2008;64(Suppl 2):S81–92.
9 Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546–54.
10 Zubenko GS, Zubenko WN, McPherson S, Spoor E, Marin DB, Farlow MR, et al. A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer’s disease. Am J Psychiat. 2003;160:857–66.
11 Lopez OL, Becker JT, Sweet RA, Klunk W, Kaufer DI, Saxton J, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer’s disease. J Neuropsych Clin Neurosci. 2003;15:346–53.
12 Park JH, Lee SB, Lee TJ, Lee DY, Jhoo JH, Youn JC, et al. Depression in vascular Dementia is quantitatively and qualitatively different from depression in Alzheimer’s Disease. Dement Geriatr Cogn Disord. 2007;23:67–73.
13 Ballard C, Bannister C, Solis M, Oyebode F, Wilcock G. The prevalence, associations and symptoms of depression amongst dementia sufferers. J Affect Disord 1996;36:135–44.
14 Ballard C, Neill D, O’Brien J, McKeith IG, Ince P, Perry R. Anxiety, depression and psychosis in vascular dementia: prevalence and associations. J Affect Disord. 2000;59:97–106.
15 Ballard C, Holmes C, McKeith I, Neill D, O’Brien J, Cairns N, et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer’s disease. Am J Psychiat. 1999;156:1039–45.
16 Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982–1983;17(1):37–49.
17 Sexton CE, Mackay CE, Ebmeier KP. A systematic review and meta-analysis of magnetic resonance imaging studies in late-life depression. Am J Geriatr Psychiatry. 2013;21(2):184–95.
18 Alexopoulos GS: Depression in the elderly. Lancet. 2005;365:1961–970.
19 Krishnan KR, Taylor WD, McQuoid DR, MacFall JR, Payne ME, Provenzale JM, Steffens DC. Clinical characteristics of magnetic resonance imaging-defined subcortical ischemic depression. Biol Psych. 2004;55:390–7.
20 Krishnan KRR, Hays JC, Blazer DG. MRI-defined vascular depression. Am J Psychiat. 1997;154:497–501.
21 Steffens DC, Krishnan KRR Structural neuroimaging and mood disorders: recent findings, implications for classification, and future directions. Biol Psych. 1998;43:705–12.
22 Pimontel MA, Reinlieb ME, Johnert LC, Garcon E, Sneed JR, Roose SP. The external validity of MRI-defined vascular depression. Int J Geriatr Psychiatry. 2013;28(11):1189–6.
23 Miniño AM, Arias E, Kochanek KD, Murphy SL, Smith BL. Deaths: final data for 2000. Natl Vital Stat Rep. 2002;50:1–119.
24 Naismith SL1, Norrie LM, Mowszowski L, Hickie IB. The neurobiology of depression in later-life: clinical, neuropsychological, neuroimaging and pathophysiological features. Prog Neurobiol. 2012;98(1):99–143.
25 Byers AL, Yaffe K. Depression and risk of developing dementia. Nat Rev Neurol. 2011;7(6):323–31.
26 Naismith SL1, Norrie LM, Mowszowski L, Hickie IB. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology. 2010;75:27–34.
27 Barnes DE1, Yaffe K, Byers AL, McCormick M, Schaefer C, Whitmer RA. Midlife vs late-life depressive symptoms and risk of dementia: Differential effects for Alzheimer Disease and vascular dementia. Arch Gen Psychiatry. 2012;69(5):493–8.
28 Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. “Vascular depression” hypothesis. Arch Gen Psychiatry. 1997;54:915–22.
29 Krishnan KR, Hays JC, George LK, Blazer DG. Six-month outcomes for MRI-related vascular depression. Depress Anxiety. 1998;8(4):142–6.
30 Alexopoulos GS. Vascular disease, depression, and dementia. J Am Geriatr Soc. 2003;51:1178–80.
31 Butters MA, Young JB, Lopez O, Aizenstein HJ, Mulsant BH, Reynolds CF 3rd, et al. Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues Clin Neurosci. 2008;10:345–57.
32 Alexopoulos GS: The vascular depression hypothesis: 10 years later. Biol Psychiatry. 2006;60:1304–5.
33 Sheline YI, Price JL, Vaishnavi SN, Mintun MA, Barch DM, Epstein AA, et al. Regional white matter hyperintensity burden in automated segmentation distinguishes late-life depressed subjects from comparison subjects matched for vascular risk factors. Am J Psychiatry. 2008;165:524–32.
34 Wolkowitz OM1, Epel ES, Reus VI, Mellon SH. Depression gets old fast: do stress and depression accelerate cell aging? Depress Anxiety. 2010;27:327–38.
35 Sierksma AS, van den Hove DL, Steinbusch HW, Prickaerts J. Major depression, cognitive dysfunction and Alzheimer’s disease: is there a link? Eur J Pharmacol. 2010;626:72–82.
36 van de Pol LA, Hensel A, Barkhof F, Gertz HJ, Scheltens P, van der Flier WM. Hippocampal atrophy in Alzheimer disease: age matters. Neurology. 2006;66:236–8.
37 Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry. 2004;161:1957–66.
38 Colla M, Kronenberg G, Deuschle M, Meichel K, Hagen T, Bohrer M, Heuser I. Hippocampal volume reduction and HPA-system activity in major depression. J Psychiatr Res. 2007;41:553–60.
39 Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet. 2006;368(9533):387–403.
40 Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131–44.
41 Caraci F1, Copani A, Nicoletti F, Drago F. Depression and Alzheimer’s disease: neurobiological links and common pharmacological targets. Eur J Pharmacol. 2010;626:64–71.
42 Cho S, Hu Y. Activation of 5-HT4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival. Exp Neurol. 2007;203:274–8.
43 Lezoualc’h F. 5-HT4 receptor and Alzheimer’s disease: the amyloid connection. Exp Neurol. 2007;205:325–9.
44 Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–56.
45 Leinonen V, Koivisto AM, Savolainen S, Rummukainen J, Tamminen JN, Tillgren T, et al. Amyloid and tau proteins in cortical brain biopsy and Alzheimer’s disease. Ann Neurol. 2010;68:446–53.
46 Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis. 2009;24:27–53.
47 Rapp MA, Schnaider-Beeri M, Purohit DP, Perl DP, Haroutunian V, Sano M.. Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depression. Am J Geriatr Psychiatry. 2008;16:168–74.
48 Rapp MA1, Schnaider-Beeri M, Grossman HT, et al. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry. 2006;63:161–7.
49 Leonard BE: Inflammation, depression and dementia: are they connected? Neurochem Res. 2007;32:1749–56.
50 Rojo LE, Fernández JA, Maccioni AA, Jimenez JM, Maccioni RB. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer’s disease. Arch Med Res. 2008;39:1–16.
51 Sorrells SF, Sapolsky RM.: An inflammatory review of glucocorticoid actions in the CNS. Brain Behav Immun. 2007;21:259–72.
52 Yaffe K, Lindquist K, Penninx BW, Simonsick EM, Pahor M, Kritchevsky S, et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology. 2003;61:76–80.
53 Fumagalli F, Molteni R, Calabrese F, Maj PF, Racagni G, Riva MA. Neurotrophic factors in neurodegenerative disorders: potential for therapy. CNS Drugs. 2008;22:1005–19.
54 Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008;455:894–902.
55 Karege F1, Vaudan G, Schwald M, Perroud N, La Harpe R. Neurotrophin levels in post-mortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res. 2005;136:29–37.
56 Angelucci F, Brenè S, Mathé AA. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry. 2005;10:345–52.
57 Murer MG, Yan Q, Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease. Prog Neurobiol. 2001;63:71–124.
58 Cotman CW: The role of neurotrophins in brain aging: a perspective in honor of Regino Perez-Polo. Neurochem Res. 2005;30:877–81.
59 Verhoeven JE, Révész D, Epel ES, Lin J, Wolkowitz OM, Penninx BWJH: Major depressive disorder and accelerated cellular aging: results from a large psychiatric cohort study. Mol Psychiatry. 2014;19:895–901.
60 Richard E, Reitz C, Honig LH, Schupf N, Tang MX, Manly JJ, et al. Late-life depression, mild cognitive impairment, and dementia. JAMA Neurol. 2013;70(3):374–82.
61 Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C, et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: Part 1. Arch Neurol. 2003;60:1385–9.
62 Adler G, Chwalek K, Jajcevic. A: Six-month course of mild cognitive impairment and affective symptoms in late-life depression. Eur Psychiat. 2004;19:502–5.
63 Lee JS, Potter GG, Wagner HR, Welsh-Bohmer KA, Steffens DC. Persistent mild cognitive impairment in geriatric depression. Int Psychoger. 2007;19:125–35.
64 Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology. 2004;63:115–21.
65 Reischies FM, Neu P. Comorbidity of mild cognitive disorder and depression – a neuropsychological analysis. Eur Arch Psy Clin N. 2000;50:186–93.
66 Butters MA, Becker JT, Nebes RD, Zmuda MD, Mulsant BH, Pollock BG, Reynolds CF 3rd. Changes in cognitive functioning following treatment of late-life depression. Am J Psychiat. 2000;157:949–54.
67 Nebes RD, Pollock BG, Houck PR, Butters MA, Mulsant BH, Zmuda MD, Reynolds CF 3rd. Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double-blind clinical trial with nortriptyline and paroxetine. J Psychiat Res. 2003;37:99–108.
68 Murphy CF, Alexopoulos GS: Longitudinal association of initiation/perseveration and severity of geriatric depression. Am J Geriat Psychiat. 2004;12:50–6.
69 Diniz BS, Sibille E, Ding Y, Tseng G, Tseng G, Aizenstein HJ, Lotrich F, et al. Plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression. Mol Psychiatry. 2015;20:594–601.
70 Olin JT, Katz IR, Meyers BS, Schneider LS, Lebowitz BD. Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background. Am J Geriat Psychiat. 2002;10:129–41.
71 Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, et al. Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriat Psychiat. 2002;10:125–8.
72 Devanand DP, Jacobs DM, Tang MX, Del Castillo-Castaneda C, Sano M, Marder K, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry. 1997;54(3):257–63.
73 Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734–6.
74 Dubois B, Albert ML. Amnestic MCI or prodromal Alzheimer’s disease? Lancet Neurol. 2004;3:246–8.
75 Tounsi H, Deweer B, Ergis AM, Van der Linden M, Pillon B, Michon A, Dubois B. Sensitivity to semantic cuing: an index of episodic memory dysfunction in early Alzheimer disease. Alzheimer Dis Assoc Disord. 1999;13:38–46.
76 Fossati P, Harvey PO, Le BG, Ergis AM, Jouvent R, Allilaire JF. Verbal memory performance of patients with a first depressive episode and patients with unipolar and bipolar recurrent depression. J Psychiatr Res. 2004;38:137–44.
77 Grober E, Buschke H. Genuine memory deficit in dementia. Dev Neuropsychol. 2006;3:13–36.
78 Buschke H, Sliwinski MJ, Kuslansky G, Lipton RB. Diagnosis of early dementia by the Double Memory Test: encoding specificity improves diagnostic sensitivity and specifi city. Neurology. 1997;48:989–97.
79 Rosén C, Hansson O, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer’s disease – current concepts. Mol Neurodegener. 2013;8:20. doi:10.1186/1750-1326-8-20.
80 Gudmundsson P, Skoog I, Waern M, Blennow K, Zetterberg H, Rosengren L, Gustafson D. Is there a CSF biomarker profile related to depression in elderly women? Psychiatry Res. 2010;176(2–3):174–8.
81 Nascimento KK, Silva KP, Malloy-Diniz LF, Butters MA, Diniz BS. Plasma and cerebrospinal fluid amyloid-β levels in late-life depression: A systematic review and meta-analysis. J Psychiatr Res 2015;69:35–41.
82 Ewers M, Mattsson N, Minthon L, Molinuevo JL, Antonell A, Popp J, et al. CSF biomarkers for the differential diagnosis of Alzheimer’s disease: A large-scale international multicenter study. Alzheimers Dement. 2015;11(11):1306–15.
83 Raedler TJ. Inflammatory mechanisms in major depressive disorder. Curr Opin Psychiatry. 2011;24(6):19–25.
84 Bay-Richter C, Linderholm KR, Lim CK, Samuelsson M, Träskman-Bendz L, Guillemin GJ,et al. A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality. Brain Behav Immun. 2015;43:110–7.
85 Wennström M, Nielsen HM, Orhan F, Londos E, Minthon L, Erhardt S. Kynurenic Acid levels in cerebrospinal fluid from patients with Alzheimer’s disease or dementia with lewy bodies. Int J Tryptophan Res. 2014;28(7):1–7.
86 Young JJ, Bruno D, Pomara N. A review of the relationship between proinflammatory cytokines and major depressive disorder. J Affect Disord. 2014;169:15–20.
87 Harrington KD, Lim YY, Gould E, Maruff P. Amyloid-beta and depression in healthy older adults: a systematic review. Aust N Z J Psychiatry. 2015;49(1):36–46.
88 Su L, Cai Y, Xu Y, Dutt A, Shi S, Bramon E. Cerebral metabolism in major depressive disorder: a voxel-based meta-analysis of positron emission tomography studies. BMC Psychiatry. 2014;14:321. doi:10.1186/s12888-014-0321-9.
89 Schmaal L, Veltman DJ, van Erp TG, Sämann PG, Frodl T, Jahanshad N, et al. Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group. Mol Psychiatry. 2016;21(6):724–5.
90 Boccia M, Acierno M, Piccardi L. Neuroanatomy of Alzheimer’s Disease and late-life depression: A coordinate-based meta-analysis of MRI studies. J Alzheimers Dis. 2015;46(4):963–70.
91 Shimoda K, Kimura M, Yokota M, Okubo Y. Comparison of regional gray matter volume abnormalities in Alzheimer’s disease and late life depression with hippocampal atrophy using VSRAD analysis: a voxel-based morphometry study. Psychiatry Res. 2015;232(1):71–5.
92 Weiner MF, Doody RS, Sairam R, Foster B, Liao TY. Prevalence and incidence of major depressive disorder in Alzheimer’s disease: findings from two databases. Dement Geriatr Cogn Disord. 2002;13:8–12.
93 Weiner MF, Edland SD, Luszczynska H. Prevalence and incidence of major depression in Alzheimer’s disease. Am J Psychiatry. 1994;151(7):1006–9.
94 Leong C. Antidepressants for depression in patients with dementia: a review of the literature. Consult Pharm. 2014;29:254–63.
95 Banerjee S, Hellier J Dewey M, Romeo R, Ballard C, Baldwin R, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet. 2011 30;378(9789):403–11.
96 Nelson JC, Devanand DP: A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc. 2011;59:577–85.
97 Sepehry AA, Lee PE, Hsiung GY, Beattie BL, Jacova C. Effect of selective serotonin reuptake inhibitors in Alzheimer’s disease with comorbid depression: a meta-analysis of depression and cognitive outcomes. Drugs Aging. 2012;29:793–806.
98 Reynolds CF 3rd1, Butters MA, Lopez O, Pollock BG, Dew MA, Mulsant BH, et al. Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry. 2011;68:51–60.
99 Lyketsos CG, DelCampo L, Steinberg M, Miles Q, Steele CD, Munro C, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003;60:737–46.
100 Roth M, Mountjoy CQ, Amrein R. Moclobemide in elderly patients with cognitive decline and depression: an international double-blind placebo-controlled trial. Br J Psychiatry. 1996;168:149–57.
101 Petracca G, Tesón A, Chemerinski E, Leiguarda R, Starkstein SE. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer’s disease. J Neuropsychiatry Clin Neurosci. 1996;8:270–5.
102 Nyth AL, Gottfries CG: The clinical efficacy of citalopram in the measurement of emotional disturbances in dementia disorders. Br J Psychiatry. 1990;157:894–901.
103 Khundakar AA, Thomas AJ: Neuropathology of depression in Alzheimer’s Disease: Current knowledge and the potential for new treatments. J Alzheimers Dis. 2015;44:27–41.
104 Cuijpers P, Sijbrandij M, Sander L, Koole SL, Andersson G, Beekman AT, Reynolds CF. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry. 2014;13(1):56–67.
105 Pinquart M, Duberstein PR, Lyness JM. Treatments for later-life depressive conditions: a meta-analytic comparison of pharmacotherapy and psychotherapy. Am J Psychiatry. 2006;163(9):1493–501.
106 Wilson KCM, Mottram PG, Vassilas CA. Psychotherapeutic treatments for older depressed people. Cochrane Database Syst Rev 2008;(1):CD004853. doi:10.1002/14651858.CD004853.pub2.
107 Peng XD, Huang CQ, Chen LJ, Lu ZC. Cognitive behavioural therapy and reminiscence techniques for the treatment of depression in the elderly: a systematic review. J Int Med Res. 2009;37(4):975–82.
108 Huang AX, Delucchi K, Dunn LB, Nelson JC. A systematic review and meta-analysis of psychotherapy for late-life depression. Am J Geriatr Psychiatry. 2015;23(3):261–73.
109 Laidlaw K. An empirical review of cognitive therapy for late life depression: does research evidence suggest adaptations are necessary for cognitive therapy with older adults? Clin Psychol Psychother. 2001;8(1):1–14.
110 Orgeta V, Qazi A, Spector AE, Orrell M. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment. Cochrane Database Syst Rev 2014;22(1):CD009125. doi:10.1002/14651858.CD009125.pub2.
111 Burgener SC, Yang Y, Gilbert R, Marsh-Yant S. The effects of a multimodal intervention on outcomes of persons with early-stage dementia. Am J Alzheimers Dis Other Demen. 2008;23(4):382–94.
112 Burns A, Guthrie E, Marino-Francis F, et al. Brief psychotherapy in Alzheimer’s disease: randomised controlled trial. Br J Psychiatry. 2005;187:143–7.
113 Apóstolo J, Queirós P, Rodrigues M, Castro I, Cardoso D. The effectiveness of nonpharmacological interventions in older adults with depressive disorders: a systematic review. JBI Database System Rev Implement Rep. 2015;13(6):220–78.
114 Kiosses DN, Teri L, Velligan DI, Alexopoulos GS. A home-delivered intervention for depressed, cognitively impaired, disabled elders. Int J Geriatr Psychiatry. 2011;26(3):256–62.
115 Kiosses DN, Ravdin LD, Gross JJ, Raue P, Kotbi N, Alexopoulos GS: Problemadaptation therapy for older adults with major depression and cognitive impairment: a randomized clinical trial. JAMA Psychiatry. 2015;72(1):22–30.
116 Webster J. Critical Advances in Reminiscence Work: From Theory to Application. New York, NY: Springer 2002.
117 Douglas S, James I, Ballard C. Non-pharmacological interventions in dementia. Adv Psychiatr Treat. 2004;10:71–9.
118 Olazarán J, Reisberg B, Clare L. Nonpharmacological therapies in Alzheimer’s disease: a systematic review of efficacy. Dement Geriatr Cogn Disord. 2010;30(2):161–78.
119 Leyhe T, Reynolds CF III, Melcher T, Linnemann C, Klöppel S, Blennow K, Zetterberg H, Dubois B, Lista S, Hampel H: A common challenge in older adults: Classification, overlap, and therapy of depression and dementia. Alzheimers Dement. 2017;13(1):59–71.